Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arcutis Biotherapeutics Inc shares valued at $17,190 were sold by Matsuda Masaru on Nov 19 ’24. At $9.68 per share, Matsuda Masaru sold 1,775 shares. The insider’s holdings dropped to 181,373 shares worth approximately $1.86 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Matsuda Masaru purchased 1,775 shares, netting a total of over 17,190 in proceeds.
Before that, Burnett Patrick had sold 69,126 shares from its account. In a trade valued at $711,618, the insider traded Arcutis Biotherapeutics Inc shares for $10.29 each. Upon closing the transaction, the insider’s holdings decreased to 69,126 shares, worth approximately $1.32 million.
As published in their initiating research note from Jefferies on August 28, 2024, Arcutis Biotherapeutics Inc [ARQT] has been a Buy and the price target has been revised to $15. Analysts at Mizuho upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early January. As of October 26, 2023, Mizuho has decreased its “Buy” rating to a “Neutral” for ARQT. Earlier on October 13, 2023, Goldman downgraded its rating. Their new recommendation was “a Neutral” for ARQT stock which previously was a “a Buy”.
Analyzing ARQT Stock Performance
During the last five days, there has been a surge of approximately 3.12%. Over the course of the year, Arcutis Biotherapeutics Inc shares have jumped approximately 217.03%. Shares of the company reached a 52-week high of $13.17 on 04/09/24 and a 52-week low of $3.07 on 01/02/24. A 50-day SMA is recorded $9.57, while a 200-day SMA reached $9.49. Nevertheless, trading volume fell to 1.46 million shares from 1.03 million shares the previous day.
Support And Resistance Levels for Arcutis Biotherapeutics Inc (ARQT)
According to the 24-hour chart, there is a support level at 9.94, which, if violated, would cause prices to drop to 9.64. In the upper region, resistance lies at 10.63. The next price resistance is at 11.02. RSI (Relative Strength Index) is 57.11 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.20, which suggests the price will decrease in the coming days. Percent R is at 38.10%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
